QUOTE AND NEWS
Benzinga  Mar 24  Comment 
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it...
TheStreet.com  Mar 2  Comment 
 DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes...
FierceBiotech  Feb 24  Comment 
La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb.
FierceBiotech  Feb 17  Comment 
A low-profile biotech in Cleveland landed a $30 million B round with the help of a new group of prominent venture backers and has been given a new CEO, a new home in La Jolla and a continuing mission to develop a drug for atrial fibrillation that...
Red Orbit  Feb 6  Comment 
Abbey Hull for redOrbit.com - Your Universe Online Two hundred miles off the coast of Central California, research biologist Brittany Hancock-Hanser and colleagues at the Marine Mammal Genetics Group at the Southwest Fisheries Science Center in...
Benzinga  Dec 16  Comment 
VeriFone Systems (NYSE: PAY) surged 5.11% to $34.75. The volume of VeriFone shares traded 427% higher than normal. VeriFone reported better-than-expected fourth-quarter results. La Jolla Pharmaceutical Co (NASDAQ: LJPC) shares rose 5.04% to...
GenEng News  Dec 10  Comment 
La Jolla Pharmaceutical obtained an exclusive worldwide license to George Washington (GW) University’s intellectual property rights related to the use of angiotensin II to treat patients with hypotension and shock. A Phase III registration...
Benzinga  Nov 13  Comment 
Revance Therapeutics (NASDAQ: RVNC) shares dipped 28.33% to $15.05 after the company reported a Q3 net loss of $14.0 million, versus a year-ago loss of $8.9 million. Local (NASDAQ: LOCM) shares fell 24.63% to $1.30 after the company reported a...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki